HB 533 — An Act amending the act of April 17, 2016 (P.L.84, No.16), known as the Medical Marijuana Act, in preliminary provisions, further providing for definitions.

PRINTER'S NO.   526

                     THE GENERAL ASSEMBLY OF PENNSYLVANIA



                         HOUSE BILL
                         No. 533
                                               Session of
                                                 2025

     INTRODUCED BY McNEILL, WAXMAN, MADDEN, GIRAL AND HOHENSTEIN,
        FEBRUARY 10, 2025

     REFERRED TO COMMITTEE ON HEALTH, FEBRUARY 10, 2025


                                    AN ACT
 1   Amending the act of April 17, 2016 (P.L.84, No.16), entitled "An
 2      act establishing a medical marijuana program; providing for
 3      patient and caregiver certification and for medical marijuana
 4      organization registration; imposing duties on the Department
 5      of Health; providing for a tax on medical marijuana
 6      organization gross receipts; establishing the Medical
 7      Marijuana Program Fund; establishing the Medical Marijuana
 8      Advisory Board; establishing a medical marijuana research
 9      program; imposing duties on the Department of Corrections,
10      the Department of Education and the Department of Human
11      Services; and providing for academic clinical research
12      centers and for penalties and enforcement," in preliminary
13      provisions, further providing for definitions.
14      The General Assembly of the Commonwealth of Pennsylvania
15   hereby enacts as follows:
16      Section 1.    The definition of "serious medical condition" in
17   section 103 of the act of April 17, 2016 (P.L.84, No.16), known
18   as the Medical Marijuana Act, is amended to read:
19   Section 103.    Definitions.
20      The following words and phrases when used in this act shall
21   have the meanings given to them in this section unless the
22   context clearly indicates otherwise:
23      * * *
 1    "Serious medical condition."        Any of the following:
 2        (1)    Cancer, including remission therapy.
 3        (2)    Positive status for human immunodeficiency virus or
 4    acquired immune deficiency syndrome.
 5        (3)    Amyotrophic lateral sclerosis.
 6        (4)    Parkinson's disease.
 7        (5)    Multiple sclerosis.
 8        (6)    Damage to the nervous tissue of the central nervous
 9    system (brain-spinal cord) with objective neurological
10    indication of intractable spasticity and other associated
11    neuropathies.
12        (7)    Epilepsy.
13        (8)    Inflammatory bowel disease.
14        (9)    Neuropathies.
15        (10)     Huntington's disease.
16        (11)     Crohn's disease.
17        (12)     Post-traumatic stress disorder.
18        (13)     Intractable seizures.
19        (14)     Glaucoma.
20        (15)     Sickle cell anemia.
21        (16)     Severe chronic or intractable pain of neuropathic
22    origin or severe chronic or intractable pain.
23        (17)     Autism.
24        (17.1)     A condition deemed a serious medical condition by
25    a practitioner.
26        (18)     Other conditions that are recommended by the
27    advisory board and approved by the secretary under section
28    1202.
29    * * *
30    Section 2.    This act shall take effect in 60 days.

20250HB0533PN0526                     - 2 -